WO2023175585 - HYBRID PROMOTERS AND THEIR USE IN OSTEOLYSIS SYNDROME
National phase entry is expected:
Publication Number
WO/2023/175585
Publication Date
21.09.2023
International Application No.
PCT/IB2023/052649
International Filing Date
17.03.2023
Title **
[English]
HYBRID PROMOTERS AND THEIR USE IN OSTEOLYSIS SYNDROME
[French]
PROMOTEURS HYBRIDES ET LEUR UTILISATION DANS LE SYNDROME D'OSTÉOLYSE
Applicants **
INNOSKEL
Inventors
GOUZE, Elvire
FAVRE, David
SARRAZY GARCIA, Stéphanie
Priority Data
63/269,514
17.03.2022
US
63/269,517
17.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2285 | |
| EPO | Filing, Examination, Granting | 10577 | |
| Japan | Filing, Examination, Granting | 2296 | |
| South Korea | Filing, Examination, Granting | 2338 | |
| USA | Filing, Examination, Granting | 8340 |
Total:
25,836
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to compositions comprising nucleic acid molecules, e.g., polynucleotides encoding a codon-optimized MAF BZIP Transcription Factor B (MafB), and/or hybrid promoters with a specific design, comprising fragments of the MafB promoter and fragments of the hEF1α promoter, which may be of interest in therapy, particularly in gene therapy. These compositions are useful for treating osteolysis syndromes, including MCTO.[French]
La présente invention concerne des compositions comprenant des molécules d'acide nucléique, par exemple, des polynucléotides codant pour un facteur de transcription B (MafB) MAF BZIP à codons optimisés, et/ou des promoteurs hybrides ayant une conception spécifique, comprenant des fragments du promoteur MafB et des fragments du promoteur hEF1α, qui peuvent présenter un intérêt en thérapie, en particulier en thérapie génique. Ces compositions sont utiles pour le traitement de syndromes d'ostéolyse, y compris MCTO.